These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 34980000)

  • 1. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
    Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
    J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
    Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
    Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
    Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
    Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
    Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
    Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
    El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
    Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
    Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
    Jain MD; Kuruvilla J
    Drugs; 2017 Oct; 77(15):1645-1655. PubMed ID: 28819821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
    Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
    Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
    Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Green MR; Monti S; Rodig SJ; Juszczynski P; Currie T; O'Donnell E; Chapuy B; Takeyama K; Neuberg D; Golub TR; Kutok JL; Shipp MA
    Blood; 2010 Oct; 116(17):3268-77. PubMed ID: 20628145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
    Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
    In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.